Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 1, 1997, Pages 420-427

  Raynaud, Florence I ^a   Orr, Rosanne M ^a   Goddard, Phyllis M ^a   Lacey, Heidi A ^a   Lancashire, Helen ^a   Judson, Ian R ^a   Beck, Terry ^b   Bryan, Bob ^b   Cotter, Finbarr E ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Genta Inc   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CODON; CYTOTOXICITY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENE EXPRESSION REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MOUSE; NONHUMAN; OPEN READING FRAME; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN BINDING; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; FEMALE; GENES, BCL-2; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES, ANTISENSE; THIONUCLEOTIDES; TISSUE DISTRIBUTION;

EID: 0031007491     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. AGRAWAL, S., TEMSAMANI, J. AND TANG, J. Y.: Pharmacokinetics, biodistribution and stability of oligodeoxynucleotides in mice. Proc. Natl. Acad. Sci, U.S.A. 88: 7595-7599, 1991.
2. BAKHSHI, A., JENSON, J. P., GOLDMAN, P., WRIGHT, J. J, MCBRIDE, O. W., EPSTEIN, A. L. AND KORSMEYER, S. J.: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around J(H) on chromosome 14 and near a transcriptional unit on 18. Cell 41: 899-906, 1985.
3. BIGELOW, J. C., CHRIN, L. R., MATHEWS, L. A. AND MCCORMACK, J. J.: Analytical and pharmacokinetic study of a phosphorothioate oligodeoxynucleotide (NSC 624958). Proc. Am. Assoc. Cancer Res. 33: 532, 1992.
4. CAMPBELL, J., BACON, T. A. AND WICKSTROM, E.: Oligodeoxynucleotide phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Methods 20: 259-267, 1990.
5. CHRISEY, L. A., PAZIRANDEH, M. AND Liss, H.: Non-sequence specific inhibition of bacterial luminescence by phosphorothioate oligodeoxyribonucleotides. Antisense Res. Dev. 5: 261-269, 1995.
6. CLEARY, M. L., SMITH, S. D. AND SKLAR, J.: Cloning and structural analysis of cDNAs for bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47: 19-28, 1986.
7. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267: 1181-1189, 1993.
8. COTTER, F. E.: Molecular pathology of lymphoma. In The Molecular Pathology of Cancer, ed. by N. R. Lemoine and N. A. Wright, pp. 157-174, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1993.
9. COTTER, F. E., CORBO, M., RAYNAUD, F., ORR, R., POCOCK, C., BRYAN, B., HARPER, M., WEBB, A., CLARKE, P., JUDSON, I. R. AND CUNNINGHAM, D.: Bcl-2 antisense therapy in lymphoma: In vitro and in vivo mechanisms, efficacy, pharmacokinetic and toxicity studies. Ann. Oncol. 7: 32, 1996.
10. COTTER, F. E., JOHNSON, P., HALL, P., POCOCK, P., AL-MAHDI, N., COWELL, J. K. AND MORGAN, G.: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9: 3049-3055, 1994.
11. CROOKE, R. M.: In vitro toxicology and pharmacokinetics of antisense oligode-oxynucleotides. Anticancer Drug Design 6: 609-646, 1991.
12. GAO, W. Y., HAN, F. S., STORM, C., EGAN, W. AND CHENG, Y. C.: Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Mol. Pharmacol. 41: 223-229, 1992.
13. GOODARZI, G., WATANABE, M. AND WATANABE, K.: Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice. Biopharm. Drug Dispos. 13: 221-227, 1992.
14. HOCKENBERY, D., NUNEZ, G., MILLIMAN, C., SCHREIBER, R. D. AND KORSMEYER, S. J.: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.) 348: 334-336, 1990.
15. 3H-1,2-Benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates. J. Am. Chem. Soc. 112: 1253-1254, 1990.
16. KIRBY, K. S.: Isolation and characterization of ribosomal ribonucleic acid. Biochem. J. 96: 266-269, 1965.
17. KRIEG, A. AND STEIN, C. A.: Phosphorothioate oligodeoxynucleotides: Antisense or antiproteins. Antisense Res. Dev. 5: 241, 1995.
18. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Polin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
19. MCCORMACK, J. J., BIGELOW, J. C., CHRIN, L. R. AND MATHEWS, L. A.: High performance liquid Chromatographic analysis of phosphorothioates in biological fluids. J. Chromatogr. 533: 133-140, 1990.
20. PAOLETTI, C.: Anti-sense oligonucleotides as potential antitumour agents: Prospective views and preliminary results. Anticancer Drug Design 2: 325-331, 1988.
21. POCOCK, C., AL-MAHDI, N., HALL, P. AND COTTER, F.: In vivo suppression of B-cell lymphoma with Bcl-2 antisense oligonucleotides. Blood 82: 200a, 1993.
22. REED, J. C., STEIN, C., SUBASINGHE, C., HALDAR, S., CROCE, C. M., YUM, S. AND COHEN, J.: Antisense mediated inhibition of BCL-2 protooncogene expression and leukemic growth and survival: Comparison of phosphodiesters and phosphorothioate oligodeoxynucleotides. Cancer Res. 50: 6565-6570, 1990.
23. SAIJO, Y., PERLAKY, L., WANG, H. AND BUSCH, H.: Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS3466 in mice. Oncol. Res. 6: 243-249, 1994.
24. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45: 932-943, 1994.
25. SRINIVASAN, S. K. AND IVERSEN, P.: Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal. 9: 129-137, 1995.
26. STEC, W. J., ZON, G., EGAN, W. AND STEC, B.: Automated solid phase synthesis, separation and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106: 6077-6079, 1984.
27. STEIN, C. A. AND COHEN, J. S.: Oligodeoxynucleotides as inhibitors of gene expression: A review. Cancer Res. 48: 2659-2688, 1988.
28. TEMSAMANI, J., TANG, J. Y. AND AGRAWAL, S.: Capped oligodeoxynucleotide phosphorothioates in mice. Ann. N.Y. Acad. Sci. 660: 318-320, 1992.
29. TIDD, D. M.: A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy. Anticancer Res. 10: 1169-1182, 1990.
30. WAGNER, R. W.: Gene inhibition using antisense oligodeoxynucleotides. Nature (Lond.) 372: 333-335, 1994.
31. WEISS, L. M., WARUKE, R. A., SKLAR, J. AND CLEARY, M. L.: Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N. Engl. J. Med. 317: 1185-1189, 1987.
32. ZHANG, R., DIASIO, R. B., Lu, Z., Liu, T., JIANG, Z., GALBRAITH, W. M. AND AGRAWAL, S.: Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type 1. Biochem. Pharmacol. 49: 929-939, 1995a.
33. ZHANG, X., Lu, Z., DIASIO, R. B., JIANG, Z., TAN, W., AGRAWAL, S. AND ZHANG, R.: Plasma and serum-protein binding of antisense oligodeoxynucleotide phosphorothioates in experimental animals and humans. Proc. Am. Assoc. Cancer Res. 36:411, 1995b.
34. ZON, G.: Oligonucleotide analogues as potential chemotherapeutic agents. Pharmacol. Res. 5: 539-549, 1988.